Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.

Novo Nordisk B

Ylin-
Alin-
Vaihto-
2026 Q2 -tulosraportti
26 päivää sitten
3,75 DKK/osake
Viimeisin osinko
3,96%Tuotto/v

Tarjoustasot

Ei dataa

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q3 -tulosraportti
4.11.
Menneet tapahtumat
2026 Q2 -tulosraportti
5.8.
2026 Q1 -tulosraportti
6.5.
Vuosittainen yhtiökokous 2026
26.3.
2025 Q4 -tulosraportti
4.2.
Ylimääräinen yhtiökokous 2025
14.11.2025

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 14 min sitten
    ·
    A study presented at ESC 2026 found a significant association between treatment with semaglutide and lower risk of cardiovascular events and death in individuals with overweight/obesity and obstructive sleep apnea (OSA), but without diagnosed diabetes. After propensity-score matching, 45,700 patients were compared between semaglutide alone and PAP treatment alone. After median 365 days of follow-up: * Semaglutide alone vs. PAP alone: approx. 80 % lower relative hazard for the combined endpoint of cardiovascular events and death (HR 0.203; 95 % CI 0.185–0.222). * Semaglutide alone vs. semaglutide + PAP: semaglutide alone was also associated with lower hazard (HR 0.527; 95 % CI 0.390–0.713). * PAP alone vs. PAP + semaglutide: PAP alone was associated with more than double the hazard (HR 2.239; 95 % CI 1.799–2.788).
  • 1 t sitten
    ·
    12 min sitten
    ·
    kentpedersen Can you not elaborate on what you mean by a daily new catastrophe from Novo? Can you also compare your explanation with the fact that there are generally side effects when taking medicine. I also understand that 27 have been awarded compensation. According to common information, there are approximately 300,000 in Denmark who have received Wegovy. Statistically, is that a lot in my opinion?
  • 2 t sitten
    ·
    Red today because fat people can't figure out how to use the medicine.
    1 t sitten
    ·
    It is, after all, made for overweight people... but just take it then.. I hope you go blind and lose the fat in your brain so we don't have to listen to you again
  • 10 t sitten
    ·
    See, now the stock is heavily undervalued, held down by the orangutan s MAGA movement 350 is just around the corner.
    1 t sitten
    ·
    Oh yes, buy some more.. don't you know that your orangutan has just ensured that novo and the other criminals have free rein.. it is hugely overvalued. 70% of revenue is based on a peptide which is incidentally toxic.. way to go
  • 13 t sitten
    Hi. I have finance background. There was a discussion below about Novo cash position. Cash flow from operations in H1 2026 was 77B DKK. Second Q was 55. I believe this means Novo will make cashflow from operations over 130B easily and it is not even close, as they are making money each week more than the week before. So, this cash flow from business operations is different from all the sand bagging going on in the accounting department, I believe this is going on, but you have to make your own assessment, this is not investment advice. And please tell me, if I am wrong, I am happy to learn and revise my opinion. I had about 5 minutes to analyze this, as it does not matter at all. This casino has nothing to do how much they earn money, as we have clearly seen. It's just feelings.
    9 t sitten
    The cashflow is high, yes, but the patent expiration date is also fast approaching... Big pharma is on a macro level all about milking the drug until the patent expires, as the profitability is limited afterwards due to significant competition. Novo Nordisk needs another wonder drug - and Amycretin is the only viable option atm.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2026 Q2 -tulosraportti
26 päivää sitten
3,75 DKK/osake
Viimeisin osinko
3,96%Tuotto/v

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 14 min sitten
    ·
    A study presented at ESC 2026 found a significant association between treatment with semaglutide and lower risk of cardiovascular events and death in individuals with overweight/obesity and obstructive sleep apnea (OSA), but without diagnosed diabetes. After propensity-score matching, 45,700 patients were compared between semaglutide alone and PAP treatment alone. After median 365 days of follow-up: * Semaglutide alone vs. PAP alone: approx. 80 % lower relative hazard for the combined endpoint of cardiovascular events and death (HR 0.203; 95 % CI 0.185–0.222). * Semaglutide alone vs. semaglutide + PAP: semaglutide alone was also associated with lower hazard (HR 0.527; 95 % CI 0.390–0.713). * PAP alone vs. PAP + semaglutide: PAP alone was associated with more than double the hazard (HR 2.239; 95 % CI 1.799–2.788).
  • 1 t sitten
    ·
    12 min sitten
    ·
    kentpedersen Can you not elaborate on what you mean by a daily new catastrophe from Novo? Can you also compare your explanation with the fact that there are generally side effects when taking medicine. I also understand that 27 have been awarded compensation. According to common information, there are approximately 300,000 in Denmark who have received Wegovy. Statistically, is that a lot in my opinion?
  • 2 t sitten
    ·
    Red today because fat people can't figure out how to use the medicine.
    1 t sitten
    ·
    It is, after all, made for overweight people... but just take it then.. I hope you go blind and lose the fat in your brain so we don't have to listen to you again
  • 10 t sitten
    ·
    See, now the stock is heavily undervalued, held down by the orangutan s MAGA movement 350 is just around the corner.
    1 t sitten
    ·
    Oh yes, buy some more.. don't you know that your orangutan has just ensured that novo and the other criminals have free rein.. it is hugely overvalued. 70% of revenue is based on a peptide which is incidentally toxic.. way to go
  • 13 t sitten
    Hi. I have finance background. There was a discussion below about Novo cash position. Cash flow from operations in H1 2026 was 77B DKK. Second Q was 55. I believe this means Novo will make cashflow from operations over 130B easily and it is not even close, as they are making money each week more than the week before. So, this cash flow from business operations is different from all the sand bagging going on in the accounting department, I believe this is going on, but you have to make your own assessment, this is not investment advice. And please tell me, if I am wrong, I am happy to learn and revise my opinion. I had about 5 minutes to analyze this, as it does not matter at all. This casino has nothing to do how much they earn money, as we have clearly seen. It's just feelings.
    9 t sitten
    The cashflow is high, yes, but the patent expiration date is also fast approaching... Big pharma is on a macro level all about milking the drug until the patent expires, as the profitability is limited afterwards due to significant competition. Novo Nordisk needs another wonder drug - and Amycretin is the only viable option atm.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Ei dataa

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q3 -tulosraportti
4.11.
Menneet tapahtumat
2026 Q2 -tulosraportti
5.8.
2026 Q1 -tulosraportti
6.5.
Vuosittainen yhtiökokous 2026
26.3.
2025 Q4 -tulosraportti
4.2.
Ylimääräinen yhtiökokous 2025
14.11.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

2026 Q2 -tulosraportti
26 päivää sitten

Uutiset

AI
Viimeisin
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q3 -tulosraportti
4.11.
Menneet tapahtumat
2026 Q2 -tulosraportti
5.8.
2026 Q1 -tulosraportti
6.5.
Vuosittainen yhtiökokous 2026
26.3.
2025 Q4 -tulosraportti
4.2.
Ylimääräinen yhtiökokous 2025
14.11.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

3,75 DKK/osake
Viimeisin osinko
3,96%Tuotto/v

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 14 min sitten
    ·
    A study presented at ESC 2026 found a significant association between treatment with semaglutide and lower risk of cardiovascular events and death in individuals with overweight/obesity and obstructive sleep apnea (OSA), but without diagnosed diabetes. After propensity-score matching, 45,700 patients were compared between semaglutide alone and PAP treatment alone. After median 365 days of follow-up: * Semaglutide alone vs. PAP alone: approx. 80 % lower relative hazard for the combined endpoint of cardiovascular events and death (HR 0.203; 95 % CI 0.185–0.222). * Semaglutide alone vs. semaglutide + PAP: semaglutide alone was also associated with lower hazard (HR 0.527; 95 % CI 0.390–0.713). * PAP alone vs. PAP + semaglutide: PAP alone was associated with more than double the hazard (HR 2.239; 95 % CI 1.799–2.788).
  • 1 t sitten
    ·
    12 min sitten
    ·
    kentpedersen Can you not elaborate on what you mean by a daily new catastrophe from Novo? Can you also compare your explanation with the fact that there are generally side effects when taking medicine. I also understand that 27 have been awarded compensation. According to common information, there are approximately 300,000 in Denmark who have received Wegovy. Statistically, is that a lot in my opinion?
  • 2 t sitten
    ·
    Red today because fat people can't figure out how to use the medicine.
    1 t sitten
    ·
    It is, after all, made for overweight people... but just take it then.. I hope you go blind and lose the fat in your brain so we don't have to listen to you again
  • 10 t sitten
    ·
    See, now the stock is heavily undervalued, held down by the orangutan s MAGA movement 350 is just around the corner.
    1 t sitten
    ·
    Oh yes, buy some more.. don't you know that your orangutan has just ensured that novo and the other criminals have free rein.. it is hugely overvalued. 70% of revenue is based on a peptide which is incidentally toxic.. way to go
  • 13 t sitten
    Hi. I have finance background. There was a discussion below about Novo cash position. Cash flow from operations in H1 2026 was 77B DKK. Second Q was 55. I believe this means Novo will make cashflow from operations over 130B easily and it is not even close, as they are making money each week more than the week before. So, this cash flow from business operations is different from all the sand bagging going on in the accounting department, I believe this is going on, but you have to make your own assessment, this is not investment advice. And please tell me, if I am wrong, I am happy to learn and revise my opinion. I had about 5 minutes to analyze this, as it does not matter at all. This casino has nothing to do how much they earn money, as we have clearly seen. It's just feelings.
    9 t sitten
    The cashflow is high, yes, but the patent expiration date is also fast approaching... Big pharma is on a macro level all about milking the drug until the patent expires, as the profitability is limited afterwards due to significant competition. Novo Nordisk needs another wonder drug - and Amycretin is the only viable option atm.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Ei dataa

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt